Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAptamer Group PLC

Aptamer Group PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.315 GBX 0.00(0%)
Last update at 2026-10-27T15:52:00Z
VOLUME
5876601
Market Cap
17.97M

Momentum Score

…

Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therapeutic applications. The company serves pharmaceutical, diagnostic, and bioprocessing companies. It has collaborations with Unilever, Neuro-Bio, the University of Glasgow, AstraZeneca, and Invizius. Aptamer Group PLC was founded in 2008 and is headquartered in York, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.31
Low
0.32
High
52 Week Price Range
0.23
Low
1.57
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.32
Dividend Yield
-
Revenue TTM
1.38M
Revenue Per Share
0.00
Gross Profit TTM
0.67M
Debt / Equity
0.36
ROE
-102.18%
Net Debt
-0.57M
ROCE
-151.48%
Diluted EPS TTM
-

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -2.57M -3.14M -8.30M -2.64M -
Net income -2.42M -2.96M -7.84M -2.09M -
Selling general administrative 2.93M 3.17M 5.03M 4.35M -
Selling and marketing expenses - 0.05M - - -
Gross profit 0.35M 0.25M 0.36M 2.69M -
Reconciled depreciation 0.23M 0.24M 0.80M 0.45M -
Ebit -2.51M -3.06M -5.56M -2.59M -2.30M
Ebitda -2.28M -2.81M -4.76M -2.14M -
Depreciation and amortization 0.23M 0.24M 0.80M 0.45M -
Operating income -2.70M -3.08M -8.16M -2.58M -
Other operating expenses 3.90M 3.94M 9.91M 6.61M -0.00M
Interest expense 0.06M 0.08M 0.13M 0.05M -
Tax provision -0.14M -0.18M -0.46M -0.55M -
Interest income 0.03M 0.02M - - -
Net interest income -0.03M -0.06M -0.13M -0.05M -
Income tax expense -0.14M -0.18M -0.46M -0.55M -0.48M
Total revenue 1.20M 0.86M 1.75M 4.04M -
Total operating expenses 3.05M 3.33M 8.52M 5.26M -
Cost of revenue 0.85M 0.61M 1.39M 1.35M -
Total other income expense net 0.13M -0.06M -0.14M -0.06M -
Net income from continuing ops -2.42M -2.96M -7.84M -2.09M -
Net income applicable to common shares - - - -2.09M -1.85M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 2.83M 2.77M 2.75M 11.52M -
Intangible assets 0.23M 0.17M 0.07M 0.34M -
Other current assets 0.15M 0.35M - 1.87M -
Total liab 1.45M 1.88M 2.45M 3.47M -
Total stockholder equity 1.38M 0.89M 0.30M 8.05M -
Other current liab 0.45M 0.38M 0.26M 1.61M 0.60M
Common stock 1.99M 0.47M 0.07M 0.07M 0.03M
Capital stock 1.99M 0.47M 0.07M 0.07M -
Retained earnings -14.86M -12.94M -10.07M -2.31M -5.40M
Other liab - - - 0.04M 0.03M
Other assets - - - 0.38M -
Cash 1.06M 0.87M 0.23M 6.69M -
Total current liabilities 1.18M 1.28M 1.64M 2.37M 1.86M
Current deferred revenue - 0.14M 0.67M - -
Net debt -0.57M -0.05M -0.17M -5.38M -
Short term debt 0.25M 0.25M 0.05M 0.25M -
Short long term debt 0.01M 0.04M 0.05M 0.04M -
Short long term debt total 0.49M 0.82M 0.07M 1.31M -
Other stockholder equity 13.63M 13.36M 10.31M 10.30M 0.27M
Property plant equipment - - - 1.82M 0.52M
Total current assets 1.82M 1.62M 1.59M 8.98M 1.32M
Net tangible assets - - - 7.71M -0.12M
Net receivables 0.53M 0.28M 0.36M 0.63M 0.85M
Long term debt 0.00M 0.01M 0.02M 0.00M -
Inventory 0.08M 0.12M 0.20M 0.42M 0.09M
Accounts payable 0.41M 0.45M 0.66M 0.51M 0.54M
Accumulated other comprehensive income 0.62M 0.50M - - -
Non currrent assets other - 0.37M 0.37M 0.38M -
Non current assets total 1.01M 1.15M 1.16M 2.54M -
Capital lease obligations 0.48M 0.77M 1.01M 1.27M -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.09M -0.12M -2.03M -0.42M -
Change to liabilities - - - 0.45M 0.57M
Total cashflows from investing activities -0.09M -0.12M - -0.42M -0.34M
Net borrowings -0.04M -0.02M - -0.41M -0.16M
Total cash from financing activities 2.28M 3.04M -0.36M 9.12M 1.50M
Net income -2.42M -2.96M -7.84M -2.09M -1.85M
Change in cash 0.19M 0.64M -6.46M 6.32M 0.06M
Begin period cash flow 0.87M 0.23M 6.69M 0.37M 0.29M
End period cash flow 1.06M 0.87M 0.23M 6.69M 0.37M
Total cash from operating activities -2.00M -2.28M -4.06M -2.38M -1.10M
Issuance of capital stock 2.89M 3.91M 0.01M 9.58M -
Depreciation 0.23M 0.24M 0.80M 0.45M 0.24M
Other cashflows from investing activities - -0.11M - - -
Change to inventory 0.04M 0.09M 0.22M -0.33M -0.02M
Change to account receivables -0.10M 0.24M - -1.43M 0.08M
Other cashflows from financing activities -0.57M -0.85M -0.33M -0.47M -0.03M
Change to netincome - - - 0.64M -0.15M
Capital expenditures 0.01M 0.12M 2.03M 0.42M 0.16M
Change in working capital -0.16M 0.02M 0.07M -1.32M -
Stock based compensation 0.12M 0.05M 0.08M 0.46M -
Other non cash items 0.24M 0.36M 0.13M 0.05M -
Free cash flow -2.01M -2.41M -6.09M -2.79M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
APTA
Aptamer Group PLC		 -
-%		 0.32 - - 13.04 7.79 11.88 -5.06
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 4.23 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 2525.51 -12.04

Profile*

Aptamer Group PLC

Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therapeutic applications. The company serves pharmaceutical, diagnostic, and bioprocessing companies. It has collaborations with Unilever, Neuro-Bio, the University of Glasgow, AstraZeneca, and Invizius. Aptamer Group PLC was founded in 2008 and is headquartered in York, the United Kingdom.

Windmill House, York, United Kingdom, YO10 5BR

44 19 0421 7404

https://aptamergroup.com

30

Name Title Year Born
Dr. Arron C. Tolley CEO, Member of the Scientific Advisory Board & Exec. Director NA
Ms. Jennifer Cutler Interim CFO & Company Sec. NA
Mr. Alastair Fleming Chief Operating Officer NA
Dr. David Bunka CTO, Member of the Scientific Advisory Board & Exec. Director NA
Dr. Arron Craig Tolley CEO, Co-Founder, Scientific Advisory Board Deputy Chair & Director 1977
Mr. Andrew Mark Rapson CFO, Company Secretary & Director 1981
Dr. David Bunka Scientific Advisory Board Chair, Chief Scientific Officer & Executive Director 1978
Dr. Arron Craig Tolley CEO, Co-Founder & Director 1977
Dr. David Bunka Chief Scientific Officer & Executive Director 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…